The condition
X-linked protoporphyria: the same light pain, from too much heme precursor
X-linked protoporphyria causes the same burning pain in visible light as erythropoietic protoporphyria, but the enzyme error runs the other way: ALAS2 is overactive, so protoporphyrin IX is overproduced. It is a minority of the EPP phenotype. Afamelanotide’s US label names EPP. The oral MC1R agonist dersimelagon was tested in both, and that Phase 3 trial met its primary endpoint.
Two genes, one phototoxic molecule. The melanocortin drug does not care which gene made the protoporphyrin. It only adds pigment in front of the light.
People with X-linked protoporphyria describe the same illness as people with erythropoietic protoporphyria: pain in the skin within minutes of daylight, including light through window glass, often with nothing a bystander can see. For years the two were not separated. They still share the photosensitiser, protoporphyrin IX. They do not share the broken step.
Too much of the first enzyme, not too little of the last
Heme in red-cell precursors starts with ALAS2, the erythroid form of 5-aminolevulinate synthase, and ends when ferrochelatase drops an iron into protoporphyrin IX. EPP is a failure of that last insertion, usually from a bad ferrochelatase allele opposite a common low-expression allele. XLP, described in 2008, is a gain of function at the start: small deletions that remove the C-terminus of ALAS2, so the enzyme runs too fast. Protoporphyrin is produced beyond what a normal ferrochelatase can clear. There is no anaemia and no iron overload of the kind other ALAS2 diseases cause.[1]
The inheritance is X-linked. Hemizygous males and heterozygous females can both be affected; a woman’s disease can be as severe as a male relative’s, or she can be nearly silent. “Erythropoietic protoporphyria, X-linked dominant” is a name that flattens that range, which is why the condition is called XLP.[1]
Among people who look as if they have EPP, sequencing finds XLP in about 2 to 10 percent.[2] A practical clue sits in the red cell before the gene result. In EPP almost all of the protoporphyrin is metal-free. In XLP a large share is zinc-chelated, on the order of 15 to 50 percent of the total.[2] Same pain, different fraction, and a reason not to stop at a clinical label of “EPP.”
Why a melanocortin drug is even relevant
Nothing about ALAS2 is a melanocortin receptor. The drug rationale is downstream of the light, not downstream of the gene. Protoporphyrin absorbs hardest around 400–410 nm and hands that energy to oxygen. MC1R agonism builds eumelanin, which sits in the skin and intercepts light before it reaches the vessel. That is the whole of the afamelanotide idea, and it does not require the porphyrin to have come from a weak ferrochelatase.
The regulatory wording is narrower than the mechanism. The US label for afamelanotide is to increase pain-free light exposure in adults with phototoxic reactions from erythropoietic protoporphyria.[3] It names EPP. It does not name XLP. The oral small-molecule MC1R agonist dersimelagon was studied in a Phase 3 trial that enrolled both, and the sponsor reported in 2026 that the trial met its primary endpoint — time in sunlight before the first warning symptom.[4]That result is a company announcement until the paper is out, and the drug is not approved. Full trial numbers and the regulatory path are on the dersimelagon page.
What pigment does not fix
A tan does not slow ALAS2 and does not remove protoporphyrin from blood or liver. A minority of people with protoporphyria develop liver injury because the liver is where the excess porphyrin is excreted and where it can precipitate. That risk belongs to the molecule, so it belongs to XLP as well as to EPP, and it is outside what an MC1R agonist is for.[2] Avoiding the triggering wavelengths, and the specialist care of the porphyria itself, are not replaced by a melanocortin.
The honest bottom line
XLP is the gain-of-function twin of EPP: too much precursor rather than too little finishing enzyme, the same phototoxic product, and the same reason a pigment drug can help without being a cure. For the shared illness, see EPP; for the two drugs, afamelanotide and dersimelagon; for the receptor, MC1R.
Education, not a protocol
This page explains X-linked protoporphyria and why melanocortin drugs are studied in it. It is not medical advice and gives no dosing or treatment instructions. See the editorial standards.
Common questions
What is X-linked protoporphyria?
X-linked protoporphyria (XLP) is a rare inherited porphyria that looks like erythropoietic protoporphyria: burning pain within minutes of visible light. The enzyme defect is the opposite of EPP. EPP cannot finish heme. XLP’s erythroid ALAS2 is overactive, so protoporphyrin IX is made faster than it can be cleared.
How common is it among people who look like they have EPP?
On the order of 2 to 10 percent of people with the EPP phenotype turn out to have XLP when the gene is sequenced. A laboratory clue is zinc-chelated protoporphyrin making up a large share of the red-cell protoporphyrin, often cited around 15 to 50 percent, instead of almost all of it being metal-free.
Does the approved melanocortin drug cover XLP?
The US label for afamelanotide names erythropoietic protoporphyria, not XLP. The pigment strategy does not care which gene overproduced the porphyrin: MC1R still builds eumelanin that absorbs light. The oral MC1R agonist dersimelagon was studied in EPP and XLP together, and that Phase 3 trial met its primary endpoint. It is not approved.
Is XLP a melanocortin disease?
No. The disease is a heme-pathway disease. Melanocortin drugs are a photoprotective workaround. They do not slow ALAS2 or clear protoporphyrin, and they do not treat the liver injury that accumulated protoporphyrin can cause in a minority of people.
References
- 1.Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet. 83(3):408–414. 2008. link ↗
- 2.Leaf RK, Dickey AK. How I treat erythropoietic protoporphyria and X-linked protoporphyria. Blood. 141(24):2921–2931. 2023. link ↗
- 3.US Food and Drug Administration. SCENESSE (afamelanotide) label: to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria. Approved indication, October 2019. The labelled disease is EPP. 2019. link ↗
- 4.Tanabe Pharma America. Positive topline results for dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). Sponsor announcement of the INSPIRE Phase 3 primary endpoint — an interested-party source. 2026. link ↗